Genera Biotech

What Genera Biotech does

Genera Biotech operates as a biotechnology-focused consulting and publishing platform that monetizes deep domain expertise and proprietary data assets across the global biopharmaceutical industry. The firm's core product is DrugPatentWatch, a database developed in 2002 that provides competitive intelligence on global drug patents and generic entry for clients throughout the drug discovery-development-delivery chain. Supporting products include the Journal of Commercial Biotechnology (a peer-reviewed publication described as 'A Harvard Business Review for Biotechnology Companies'), the Building Biotechnology textbook (used as a course text in dozens of MBA and graduate biotechnology programs), BiotechBlog (a guest-post content platform), and the Scientific American worldVIEW global biotechnology scorecard covering more than fifty countries. The company is operated as a founder-led micro-firm with 1-10 employees, centered on Dr. Yali Friedman, Ph.D., who acts as principal author, editor, speaker, and expert witness.

The business model is content-led and contact-based: revenue is generated through subscription-style publishing, sponsored articles and content marketing on DrugPatentWatch's resource section reaching more than 20,000 opt-in email subscribers, expert witness testimony, paid speaking engagements for US federal agencies, international groups (APEC, ASEAN), and individual country governments, plus book royalties and journal subscriptions. No ecommerce or self-serve platform is disclosed; all services are accessed via contact forms. The go-to-market motion is thought leadership and personal-brand driven rather than product-led growth. The company has operated continuously since 2002 without disclosed external funding, parent company, or subsidiary structure, and serves a diversified customer base spanning enterprise pharmaceutical companies, US and international government bodies, and academic biotechnology education programs.

Name

Genera Biotech

Legal name

thinkBiotech

Website

https://generabiotech.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

Genera Biotech (operating as thinkBiotech) is a founder-led biotechnology consulting and publishing platform that provides global drug patent intelligence via DrugPatentWatch, alongside peer-reviewed publishing, textbooks, and expert-witness and speaking services for pharmaceutical, government, and academic clients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Intelligence

NAICS

Directory and Mailing List Publishers (513140), Software Publishers (5132)

SIC

Miscellaneous Publishing (2741), Books: Publishing Or Publishing & Printing (2731), Periodicals: Publishing Or Publishing & Printing (2721)

akta.pro industry

PRIMARYHLAGAJAN

Knowledge Management & Scientific Collaboration / Literature Intelligence

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYEDABALAU

Pharmaceuticals & Biotechnology

Education/Corporate Training & Professional Development/Industry-Specific Professional Training (e.g., Healthcare, Manufacturing, Construction)

SECONDARYEDAGABAG

Medicine & Allied Health (Clinical)

Education/Educational Publishing & Learning Content/Higher Education Textbooks & Courseware

Keywords

• Drug patent intelligence
• Biotechnology consulting services
• Pharmaceutical market research
• Biotech industry publishing
• Biotech education resources

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Publishing and Content: The Journal of Commercial Biotechnology is published, along with book publishing (Building Biotechnology, Best Practices in Biotechnology Education, Best Practices in Biotechnology Business Development). The Journal serves as a knowledge product reaching industry professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Genera Biotech distributes biopharmaceutical intelligence and educational content through the DrugPatentWatch.com platform, the Journal of Commercial Biotechnology, the Building Biotechnology textbook, and global biotechnology rankings research. It also delivers expert witness, speaking, and consulting services to pharmaceutical companies, government agencies, and biotechnology educational programs.

Product overview

Genera Biotech (via thinkBiotech) offers a portfolio of biopharmaceutical intelligence and educational products centered around DrugPatentWatch, a competitive intelligence platform for drug patents and generic entry analysis. Supporting offerings include the Journal of Commercial Biotechnology (a peer-reviewed publication), Building Biotechnology (an educational textbook), BiotechBlog (a content platform for guest posts), and Global Biotechnology Rankings research services. The core platform is DrugPatentWatch, supplemented by publishing and consulting services.

Differentiator

Problem solved

Functional benefit

Brands

• DrugPatentWatch.com: Pharmaceutical industry competitive intelligence platform providing deep knowledge on global drug patents and generic entry for clients throughout the drug discovery-development-delivery chain.
• Journal of Commercial Biotechnology
• BiotechBlog.com

Products and services

• DrugPatentWatch Proprietary database platform providing deep knowledge on global drug patents and generic entry for clients throughout the drug discovery-development-delivery chain, including a resources section with reach to tens of thousands of focused readers.
• Journal of Commercial Biotechnology Peer-reviewed journal covering biotechnology business and commercialization topics for executives, entrepreneurs, and professionals in the biopharmaceutical industry.
• Building Biotechnology Textbook on biotechnology commercialization used as a course text in dozens of MBA programs and graduate programs in biotechnology.
• Global Biotechnology Rankings Research service providing a global biotechnology perspective that profiles biotechnology industries and innovation capacity in more than fifty countries, originally featured in the Scientific American worldVIEW scorecard.
• Expert Witness and Consulting Services Expert witness testimony, speaking engagements, and biotechnology commercialization consulting provided to pharmaceutical companies, US federal agencies, intergovernmental groups (APEC, ASEAN), and individual country governments.

Quantifiable outcome

• Reaches more than 20,000 targeted opt-in email subscribers in patent and generic biopharmaceutical space
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered minor and core.

• NY TimesminorOthersDr. Friedman created the first blog on the business of biotechnology for a NY Times web property, which was named to Forbes Best of the Web list. This appears to be a content/ publishing partnership rather than a commercial arrangement.
• Scientific AmericancoreStrategic or Co-development PartnerDr. Friedman is editor of the Scientific American worldVIEW global biotechnology scorecard, profiling biotechnology industries and innovation capacity in more than fifty countries. This is an ongoing editorial and intellectual property partnership for global biotechnology rankings.
• FUJI TelevisionminorStrategic or Co-development PartnerSponsored the Student Guide to DNA Based Computers project, indicating a content sponsorship/collaboration relationship.
• APEC and ASEANminorOthersDr. Friedman has been invited to participate in biotechnology industry development forums for international groups such as APEC and ASEAN, providing expert consultation and speaking services.

Scale indicators6 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Evaluate Pharma: Evaluate Pharma provides commercial intelligence, forecasts, and analysis for the pharmaceutical and biotech industry, covering drug sales, pipelines, patent expiries, and competitive dynamics. It is a direct competitor to the strategic intelligence layer DrugPatentWatch offers, particularly for pharma business development and competitive strategy teams.
• Endpoints News: Endpoints News is a daily biopharma industry news and analysis outlet covering drug development, business strategy, and commercial decisions. It competes for the same biopharma executive audience that thinkBiotech serves through JCB, BiotechBlog, and DrugPatentWatch content.
• FierceBiotech: FierceBiotech is an industry news and analysis publication targeting biopharma executives with daily coverage of drug development, business strategy, and commercial intelligence. It overlaps with thinkBiotech's content-led approach to reaching biotech decision-makers.
• PatSnap: PatSnap is an AI-powered patent intelligence and innovation analytics platform that, like DrugPatentWatch, helps pharmaceutical and life sciences teams analyze patent landscapes, expiry timelines, and competitive intelligence. It is the closest direct competitor in patent intelligence for the drug discovery-to-delivery value chain.
• Drug Discovery & Development: Drug Discovery & Development is an industry publication covering drug discovery, development, and commercial strategy for pharmaceutical and biotech professionals. It overlaps with DrugPatentWatch and BiotechBlog for audience attention among drug development strategists and business development leaders.
• BioCentury: BioCentury is a long-running subscription-based intelligence, analysis, and commentary publication serving biopharmaceutical business development and strategy professionals. Its audience and commercial model closely mirror the Journal of Commercial Biotechnology and DrugPatentWatch subscribers.
• Nature Biotechnology: Nature Biotechnology is a leading peer-reviewed journal covering biotechnology science and commercialization. It is the closest comparable peer-reviewed publication to the Journal of Commercial Biotechnology, competing for the same biopharma executive and researcher readership.

Broad incumbents

• IQVIA: IQVIA is a global life sciences analytics and clinical research company offering commercial intelligence, market access data, and competitive insights for pharmaceutical companies. It serves the same biopharma strategy and commercial teams as DrugPatentWatch, but as one capability within a much larger services portfolio.
• Clarivate: Clarivate is a large, diversified intellectual property analytics and scientific intelligence company offering patent search, landscape analysis, and competitive intelligence tools through products such as Derwent and CompuMark. It competes with DrugPatentWatch in the same buyer workflow but serves a much broader IP and life sciences customer base.

Others

• Biotechnology Innovation Organization (BIO): BIO is the largest biotechnology industry trade association, producing industry reports, policy advocacy, and the BIO International Convention. While not a direct commercial competitor, BIO shapes the same biopharma business and policy audience that thinkBiotech serves through its rankings, journal, and government forums.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/media
• Facebookfacebook.com/genera.biotech
• LinkedInlinkedin.com/company/genera-biotech-sl

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genera Biotech